Price Point Analysis for Laboratory Developed Tests (LDTs) and FDA Regulated Tests

Price Point Analysis for Laboratory Developed Tests (LDTs) and FDA Regulated Tests

Discover the Perfect Assay Price Point to Remain Competitive

RELEASE DATE
12-Sep-2016
REGION
North America
Research Code: 9AB9-00-55-00-00
SKU: HC02677-NA-MR_18988
AvailableYesPDF Download
$1,500.00
In stock
SKU
HC02677-NA-MR_18988
$1,500.00
DownloadLink
ENQUIRE NOW

Description

The main objective of this research is to estimate test volumes and unit prices for a wide variety of LDTs (genetic) and a few high volume FDA tests for selective therapeutic areas. The tests are categorized by their intended uses across the diagnostic spectrum (risk assessment, screening, diagnosis, staging and prognosis, therapy selection, therapy monitoring). A selective list of therapeutic areas covered in this research include: autoimmune diseases, cancers (breast, colorectal, prostrate, lung, gastric, cervical, and ovarian), toxicology, cardiology, women’s health (vitamin D, prenatal, pregnancy and hormone), and infectious disease testing (TB, hepatitis A/B/C, cytomegalovirus). The base year used for analysis is 2015.

Table of Contents

Research Scope

Executive Summary

Executive Summary (continued)

Executive Summary (continued)

Research Objectives

Abbreviations

Celiac Disease Specific LDT Assays

Chron’s Disease Specific LDT Assays

Rheumatoid Arthritis Specific LDT Assays

Lupus Specific LDT Assays

LupusSpecific LDT Assays (continued)

IBD and IBS Specific LDT Assays

Biomarker Guidelines

Cardiac Disease Specific LDTs and FDA Assays

Cardiac Disease Specific LDTs and FDA Assays (continued)

Prostate Cancer Specific LDT Assays

Prostate Cancer Specific LDT Assays (continued)

Breast Cancer Specific LDT Assays

Breast Cancer Specific LDT Assays (continued)

Breast Cancer Specific LDT Assays (continued)

Colon Cancer Specific LDT and CLIA Waived Assays

Colon Cancer Specific LDT and CLIA Waived Assays (continued)

Colon Cancer Specific LDT and CLIA Waived Assays (continued)

Lung Cancer Specific LDT and FDA Assays

Lung Cancer Specific LDT and FDA Assays (continued)

Gynecologic Cancers (Ovarian)Specific LDT and FDA Assays

Gynecologic Cancers (Cervical)Specific LDT and FDA Assays

Biomarker Guidelines

Gastric Cancer/GIST Specific LDT and FDA Assays

Women’s Health Vitamin D Tests

Women’s Health Prenatal Tests

Women’s Health Pregnancy and Hormone Tests

Toxicology Popularly Ordered Tests

Infectious Diseases Popularly Ordered Genetic Tests

Infectious Diseases Popularly Ordered Tests

Legal Disclaimer

The Frost & Sullivan Story

Value Proposition—Future of Your Company & Career

Global Perspective

Industry Convergence

360º Research Perspective

Implementation Excellence

Our Blue Ocean Strategy

Related Research
The main objective of this research is to estimate test volumes and unit prices for a wide variety of LDTs (genetic) and a few high volume FDA tests for selective therapeutic areas. The tests are categorized by their intended uses across the diagnostic spectrum (risk assessment, screening, diagnosis, staging and prognosis, therapy selection, therapy monitoring). A selective list of therapeutic areas covered in this research include: autoimmune diseases, cancers (breast, colorectal, prostrate, lung, gastric, cervical, and ovarian), toxicology, cardiology, women’s health (vitamin D, prenatal, pregnancy and hormone), and infectious disease testing (TB, hepatitis A/B/C, cytomegalovirus). The base year used for analysis is 2015.
More Information
No Index No
Podcast No
Author Divyaa Ravishankar
Industries Healthcare
WIP Number 9AB9-00-55-00-00
Is Prebook No